FDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock Up

The FDA recommended a Type B pre-BLA meeting with Rezolute as a precursor to a potential BLA submission for ersodetug, intended to treat hypoglycemia caused by congenital hyperinsulinism. The recommendation is a regulatory step toward a possible application, not an approval or confirmation that a BLA will be submitted.